nach oben

Erschienen in:

01.10.2010 | Original

Critical care management of patients with hemophagocytic lymphohistiocytosis

verfasst von: Sophie Buyse, Luis Teixeira, Lionel Galicier, Eric Mariotte, Virginie Lemiale, Amélie Seguin, Philippe Bertheau, Emmanuel Canet, Adrienne de Labarthe, Michaël Darmon, Michel Rybojad, Benoit Schlemmer, Elie Azoulay

Erschienen in: Intensive Care Medicine | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition associated with multiple organ dysfunction. We sought to describe ICU management and outcomes in HLH patients meeting HLH-2004 criteria and to identify determinants of mortality.

Design

Retrospective study between January 1998 and January 2009.

Setting

Medical ICU of a teaching hospital.

Patients

Among the 72 patients fulfilling the HLH-2004 criteria, we report the 56 patients with complete follow-up and no missing data.

Interventions

None.

Measurements and main results

Clinical and laboratory data were abstracted from the medical records. Median SOFA score at admission was 6.5 (IQR, 4–8). At ICU admission, the number of HLH-2004 criteria was 6 (5–7). Sixty-six precipitating factors were found in 52 patients and consisted of 43 tumoral causes (8 Castleman’s diseases, 18 B cell lymphoma and 17 various malignancies), 13 non-viral infections and 10 viral infections. Underlying immune deficiency was present in 38 (67.8%) patients. Etoposide was used in 45 patients, corticosteroids in 31 and intravenous immunoglobulins in 3. Mechanical ventilation was required in 32 patients, vasoactive agents in 30 and renal replacement therapy in 19. Hospital mortality was 29/56 patients. By multivariate analysis, factors associated with increased hospital death were shock at ICU admission [OR, 4.33; 95% confidence interval (95% CI), 1.11–16.90; P = 0.03] and platelet count <30 g/l (OR, 4.75; 95% CI, 1.20–18.81; P = 0.02). B cell lymphoma [odds ratio (OR), 0.17; 95% CI, 0.04–0.80; P = 0.02] and Castleman’s disease (OR, 0.11; 95% CI, 0.02–0.90; P = 0.04) were associated with increased hospital survival.

Conclusions

Aggressive supportive care combined with specific treatment of the precipitating factor can produce meaningful survival in patients with HLH responsible for multiple organ failures. Survival is highest in patients with HLH related to Castleman’s disease or B cell lymphoma.

Nur mit Berechtigung zugänglich

Wilson RF (1981) Etiology, diagnosis, and prognosis of positive blood cultures. Am Surg 47:112–115PubMed

Gauvin F, Toledano B, Champagne J, Lacroix J (2000) Reactive hemophagocytic syndrome presenting as a component of multiple organ dysfunction syndrome. Crit Care Med 28:3341–3345CrossRefPubMed

Janka GE (2005) Hemophagocytic lymphohistiocytosis. Hematology 10(Suppl 1):104–107CrossRefPubMed

Henter JI, Elinder G, Ost A (1991) Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 18:29–33PubMed

Janka GE (2007) Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 166:95–109CrossRefPubMed

Castillo L, Carcillo J (2009) Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 10:387–392CrossRefPubMed

Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131CrossRefPubMed

Creput C, Galicier L, Buyse S, Azoulay E (2008) Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. Intensive Care Med 34:1177–1187CrossRefPubMed

Risdall RJ, Brunning RD, Hernandez JI, Gordon DH (1984) Bacteria-associated hemophagocytic syndrome. Cancer 54:2968–2972CrossRefPubMed

10.

Grom AA (2003) Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 15:587–590CrossRefPubMed

11.

Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40:1285–1292CrossRef

12.

Strauss R, Neureiter D, Westenburger B, Wehler M, Kirchner T, Hahn EG (2004) Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients–a postmortem clinicopathologic analysis. Crit Care Med 32:1316–1321CrossRefPubMed

13.

Stephan F, Thioliere B, Verdy E, Tulliez M (1997) Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis 25:1159–1164CrossRefPubMed

14.

Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Sakamoto M, Nishiwaki K, Masuoka H, Shimada T, Yoshida M, Hosoya T (1997) Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59:247–253CrossRefPubMed

15.

Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, Dupond JL, Larroche C, Piette AM, Mechenstock D, Ziza JM, Arlaud J, Labussiere AS, Desvaux A, Baty V, Blanche P, Schaeffer A, Piette JC, Guillevin L, Boissonnas A, Christoforov B (2003) Reactive hemophagocytic syndrome in adult systemic disease: report of 26 cases and literature review. Arthritis Rheum 49:633–639CrossRefPubMed

16.

Imashuku S (2000) Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol 72:1–11PubMed

17.

Peigne V, Rusinova K, Karlin L, Darmon M, Fermand JP, Schlemmer B, Azoulay E (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35:512–518CrossRefPubMed

18.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710CrossRefPubMed

19.

Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H (1997) Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 103:114–120CrossRefPubMed

20.

Yang K, Azoulay E, Attalah L, Zahar JR, Van de Louw A, Cerf C, Soussy CJ, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2003) Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation. Intensive Care Med 29:396–402PubMed

21.

Delclaux C, Azoulay E (2003) Inflammatory response to infectious pulmonary injury. Eur Respir J Suppl 42:10s–14sCrossRefPubMed

22.

Azoulay E, Delclaux C (2004) Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients? Intensive Care Med 30:10–17CrossRefPubMed

23.

Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, Camus C, Fauchet R, Thomas R, Drenou B (2004) Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 169:1144–1151CrossRefPubMed

24.

Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC, Hamoudi R, Daniel MT, Agbalika F, Boshoff C, Clauvel JP, Isaacson PG, Meignin V (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331–2336CrossRefPubMed

25.

Scott D, Cabral L, Harrington WJ Jr (2001) Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol 66:148–150CrossRefPubMed

26.

Fardet L, Coppo P, Kettaneh A, Dehoux M, Cabane J, Lambotte O (2008) Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 58:1521–1527CrossRefPubMed

27.

Jones AE, Trzeciak S, Kline JA (2009) The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 37:1649–1654CrossRefPubMed

28.

Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, Fermand JP, Schlemmer B (1999) Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med 25:1395–1401CrossRefPubMed

29.

Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, Arakawa H, Sotomatsu M, Kataoka S, Asami K, Hasegawa D, Kosaka Y, Sano K, Igarashi N, Maruhashi K, Ichimi R, Kawasaki H, Maeda N, Tanizawa A, Arai K, Abe T, Hisakawa H, Miyashita H, Henter JI (1999) Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 93:1869–1874PubMed

Titel: Critical care management of patients with hemophagocytic lymphohistiocytosis
verfasst von: Sophie Buyse
Luis Teixeira
Lionel Galicier
Eric Mariotte
Virginie Lemiale
Amélie Seguin
Philippe Bertheau
Emmanuel Canet
Adrienne de Labarthe
Michaël Darmon
Michel Rybojad
Benoit Schlemmer
Elie Azoulay
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 10/2010
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-010-1936-z

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Critical care management of patients with hemophagocytic lymphohistiocytosis